<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192971</url>
  </required_header>
  <id_info>
    <org_study_id>HENGRUI20100510</org_study_id>
    <nct_id>NCT01192971</nct_id>
  </id_info>
  <brief_title>A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma</brief_title>
  <acronym>HCC</acronym>
  <official_title>Single Arm, Open-label, Multi-center, Phase II Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eighty-One Hospital of People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial will be studying how well Apatinib working in patients with liver cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TTP (Time To Progression)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival safety</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR (Disease control rate</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (objective response rate)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL (quality of life)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>A 850</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 850: Experimental apatinib 850 mg qd, and it should be continued until disease progression or intolerable toxicity or patient withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B750</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B750: apatinib 750 qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>apatinib p.o. once daily for 4 weeks</description>
    <arm_group_label>A 850</arm_group_label>
    <arm_group_label>B750</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologic confirmed advanced hepatocellular carcinoma

          -  Life expectancy of more than 3 months.

          -  ECOG performance scale 0 - 2.

          -  No cirrhosis with child -pugh score A

          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan.

          -  Adequate hepatic, renal, heart, and hematologic functions (platelets &gt; 90 × 109/L,
             neutrophil &gt; 1.5 × 109/L, serum creatinine ≤ 1.5mg/dl, total bilirubin within upper
             limit of normal(ULN), and serum transaminase≤2.5×the ULN).

          -  signed and dated informed consent.Willingness and ability to comply with scheduled
             visits, treatment plans, laboratory tests, and other study procedure.

        Exclusion Criteria:

          -  Pregnant or breastfeeding women

          -  History of any second malignancies within 3 years except cured basal cell carcinoma of
             skin and carcinoma in-situ of uterine cervix

          -  Any factors that influence the usage of oral administration

          -  Evidence of CNS metastasis

          -  Intercurrence with one of the following: hypertension, coronary artery disease,
             arrhythmia and heart failure

          -  Receiving the therapy of thrombolysis or anticoagulation

          -  Abuse of alcohol or drugs

          -  Less than 4 weeks from the last clinical trial

          -  Disability of serious uncontrolled intercurrence infection.

          -  Treatment with potent CYP3A4 inhibitors and inducer with 7 and 12 days respectively,
             prior to study drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shukui Qin, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Millitary Eighty-one Hosiptal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjin Military Eighty -one Hosiptal</name>
      <address>
        <city>Nanjin,</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dr Qin Shukui</name_title>
    <organization>Millatary Eighty-one Hospital</organization>
  </responsible_party>
  <keyword>hcc, apatinib, phase II, cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

